Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Final development and commercial preparation of Phactory™, a universal platform technology to enable scalable phagebased drug development and production

Project description

New tech for phage-based drug production

The rise of drug-resistant bacteria underscores the need for alternative therapies that target these pathogens while protecting the patient’s microbiome. Bacteriophages (phages) are effective against multidrug-resistant bacteria and can selectively eliminate specific pathogens. However, current phage production processes raise biosafety concerns and are often inefficient and difficult to scale. Invitris has revolutionised phage development with its Phactory™ platform, enabling scalable and personalised production of phage-based drugs. The EU-funded Phactory project will utilise support from the European Innovation Council (EIC) to standardise the clinical production process of Phactory™ and conduct clinical trials to validate the efficacy and safety of novel phage-based therapies.

Objective

The rise of drug-resistant bacteria necessitates the development of alternative therapies that can specifically target and eliminate these pathogens while minimizing harm to the patient's microbiome. Bacteriophages (phages) are potent therapeutics that can fight multidrugresistant pathogenic bacteria. Unlike broad-spectrum antibiotics, phages can selectively eliminate bacteria. However, the current production processes for phages pose considerable biosafety concerns and are often relatively inefficient, unreliable, and unscalable. Invitris has fundamentally transformed the way phages can be developed with its unique in vitro platform technology, Phactory™. For the first time, Phactory™ enables scalable, personalized production and rapid engineering of novel drugs based on phages. We aim to leverage the support by EIC to standardize the clinical production process of Phactory™ and conduct clinical trials to validate the efficacy and safety of novel phage-based therapies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

INVITRIS
Net EU contribution
€ 2 499 999,00
Address
AM KLOPFERSPITZ 19
82152 Planegg-Martinsried
Germany
SME
Yes
Region
Bayern Oberbayern München, Landkreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data